The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | SCIENCE: chemoradiotherapy combined with sintilimab achieves high pCR rate
Xuefeng Leng, MD, PhD, University of Electronic Science and Technology of China (UESTC), Chengdu, China, presents promising results from the Phase III SCIENCE trial (NCT05244798), which compared chemoradiotherapy (CRT) with sintilimab to chemotherapy with sintilimab and CRT alone, in resectable locally advanced esophageal squamous cell carcinoma (ESCC). The study’s primary endpoint showed a remarkably high pathological complete response (pCR) rate in the CRT plus sintilimab group, compared to lower results in the other arms. While long-term survival data is still pending, these short-term results establish the potential of this combination treatment in improving outcomes. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
